English | 简体中文 | 繁體中文 | 한국어
Nexstim Plc Signs Canadian Distribution Agreement for its SmartFocus(TM) TMS systems with Canadian Health Solutions CHS

Press release, Helsinki, 7 January 2019 at 1.00 pm EET

Nexstim Plc Signs Canadian Distribution Agreement for its SmartFocus(TM) TMS systems with Canadian Health Solutions CHS

Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depression Disorder (MDD), announces it has signed a distribution agreement with Canadian Health Solutions to bring its SmartFocus(TM) TMS system to the Canadian market. The system is expected to be launched in Canada in the next few months.

Dr. David Elias, CEO of Canadian Health Solutions CHS, commented: "An estimated 10 per cent of Canadians use health services for mood and anxiety disorders annually.  According to Statistics Canada, 1,330,510Canadians over the age of 15 reported indicators for 'Major depression episode' in 2012*. Canadian Health Solutions ispleasedto be the distributor for Nexstim's NBT® system, which is based on a unique transcranial magnetic stimulation (TMS) technology. Based upon our deep understanding and research into mental health issues, we believe Nexstim's system has great potential and could significantly benefit the large number of Canadians who are in need of improved treatment options for MDD."

Nexstim SmartFocusTM technology is differentiated by its sophisticated 3D navigation that uses its proprietary E-field algorithm to visualize the exact location, orientation and magnitude of the stimulation given to the brain to treat MDD.

Dr. David Elias continued: "Canadian Health Solutions has a successful record of development, implementation and delivery of tailored health solutions. Cost effectiveness and validated health outcomes are required for all our solutions. We are happy to partner with Nexstim in making TMS available to Canadians."

The distribution agreement covers both Nexstim's NBT® system for the treatment of MDD as well as the Nexstim NBS® system for presurgical mapping.

Martin Jamieson, Chairman and CEO of Nexstim Plc, said: "We are delighted to announce that we have signed an agreement with Canadian Health Solutions that has a long experience in implementing and delivering health solutions into the Canadian market. This agreement is an important step supporting our strategy to expand in North America, where we believe there is a significant commercial opportunity for our clearly differentiated NBT® system for the treatment of MDD. "

*2012 Canadian Community Health Survey https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310046501  


Further information is available on the website www.nexstim.com or by contacting:

Martin Jamieson, Chairman and CEO
+44 771 516 3942
[email protected]

Citigate Dewe Rogerson       
David Dible/Shabnam Bashir/ Sylvie Berrebi
+44 (0)207 2822949
[email protected]

About Nexstim Plc
Nexstim is a medical technology company focused on the development and commercialization of its world-leading SmartFocusTM TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company's proprietary Navigated Brain Therapy (NBT®) system, a highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.

Nexstim's NBT® system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBT® system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.

For more information please visit www.nexstim.com .

About Canadian Health Solutions CHS:www.canadianhealthsolutions.ca

This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire

Copyright © Thomson Reuters 2019. All rights reserved.
Press Releases
FRO - Update Regarding Front Altair  
June 14, 2019 21:30 ET
Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001)  
June 14, 2019 08:30 ET
Ole Martin Grimsrud Appointed CFO of Aker Solutions  
June 14, 2019 07:00 ET
REC Silicon - Delay Moses Lake shutdown decision until July 15  
June 13, 2019 21:00 ET
June 13, 2019 15:43 ET
Verisk Financial Helps Neobank Xinja Ensure APRA Compliance  
June 4, 2019 22:29 ET
Curt Espeland to address the Deutsche Bank Global Industrials & Materials Summit  
May 30, 2019 22:29 ET
Lubrizol to Present at the 29th CIMAC World Congress 2019  
May 28, 2019 21:59 ET
Particle Sciences Expands Controlled Substance Capabilities with Approval of DEA Schedule I Registration  
May 28, 2019 20:29 ET
Forbes ranks Eastman as one of the Best Large Employers in America  
May 21, 2019 22:29 ET
More News >>
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: